Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Foto: Lægemiddelstyrelsen / Pr

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Foto: Lægemiddelstyrelsen / Pr

Other

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

The Danish Medicines Agency seeks to bring the matter to European inspectors to increase awareness of potential problems in the future.

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Despite promising results, one analyst thinks patients will have to wait for higher doses of diabetes pill Rybelsus until 2025.

For subscribers

Pharma & biotech

Zealand Pharma presents positive early-stage results for weight-loss candidate

The Danish biotech company is encouraged, although more testing will be needed ”to fully assess the clinical potential” of a new obesity treatment candidate.

For subscribers

Did you read?

Obesity drug hit makes Novo Nordisk more valuable than Nestle

The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years.

For subscribers

Pharma & biotech

Genmab promotes senior VP for strategy to executive management

Martine van Vugt, a veteran at Genmab, has risen through the ranks.

For subscribers

Medtech

Ambu wins European approval of two fifth-generation bronchoscopes

With two recent approvals, the Danish medtech company says it now offers a full portfolio of single-use bronchoscopes.

For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Jobs

See all jobs

Foto: Christopher Due Karlsson / Medwatch

Pharma & biotech

Novo Nordisk chair boasts competitive production advantage

The Danish drugmaker’s chair says the company’s production facilities makes it one to watch, and Novo Nordisk is only increasing its investments into expanding capacity in 2023.

For subscribers

Did you read?

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

For subscribers

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

For subscribers

Initial probes pointed to the contamination coming from the capsules containing Dicillin, or the drug's packaging | Foto: Lægemiddelstyrelsen / Pr

Other

Production at contaminated CMO continues – authorities deny further risks

The Danish Medicines Agency says shutting down the one production line specifically making the contaminated Dicillin is adequate, although the root cause is still unknown.

For subscribers

Glenn Saldanha is chairman at the board of Glenmark | Foto: Danish Siddiqui/Reuters/Ritzau Scanpix

Pharma & biotech

Indian generic drugmaker to launch Leo Pharma copycat drug in US

Generic drugmaker Glenmark has received 180-day generic drug exclusivity on one of Leo Pharma’s inventions.

For subscribers

Regulation

EU delays new drug law proposal

A busy few weeks means the Commission is unable to present its proposal for overhauled pharma legislation, which was anticipated on March 29.

For subscribers

Did you read?

Novo Nordisk enters collaboration with AI-driven drug discovery company

Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis.

For subscribers

Article series: Pharma & biotech

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

For subscribers

Read the article here

Pharma & biotech

Obesity drug hit makes Novo Nordisk more valuable than Nestle

The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years.

For subscribers

Pharma & biotech

Novo Nordisk enters collaboration with AI-driven drug discovery company

Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis.

For subscribers

California is taking a USD 50m step toward its ambition to make its own insulin products | Foto: George Frey/Reuters/Ritzau Scanpix

Pharma & biotech

California moves forward with making biosimilar insulin

The state has entered a contract with generic drugmaker Civica to make insulin products that are interchangeable with those of Novo Nordisk, Sanofi, and Eli Lilly.

For subscribers

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

One of the Danish drugmaker’s partnered patient organizations did not disclose ties to Novo Nordisk in promotional material for obesity treatment.

For subscribers

Pharma & biotech

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

The very top of the Danish drugmaker has only grown more distant to its own goal of ensuring 45% male/female representation across leadership teams.

For subscribers

Other

Top news from MedWatch this week

Miss anything?

Medtech

Ambu share offering complete at 4.7% discount

The Danish medtech company has raised DKK 1.1bn.

For subscribers

Medtech

Nordnet sees reason in Ambu's speedy capital raise

”Ambu should now consider itself as financially free as bird and ready to soar,” assesses a Nordnet analyst.

For subscribers

Helge Lund, chairman at the board of directors at Novo Nordisk | Foto: Christopher Due Karlsson / Medwatch

Pharma & biotech

Novo Nordisk board discussed supply issues at every meeting in 2022

How to meet surging demand for some of the Danish drugmaker’s most popular drugs was amongst the most debated topics at the year’s board meetings, Chair Helge Lund says.

For subscribers

Medtech

Novo Holdings could earn big on acquisition bid for Synlab

With 17% ownership of the laboratory services provider, Novo Holdings would likely make a pretty penny if an acquisition offer is accepted.

For subscribers

Pharma & biotech

Patient group did not disclose Novo Nordisk ties in obesity treatment campaign

Novo Nordisk has led a hidden obesity treatment marketing campaign on Danish pharmacies’ websites in collaboration with an independent patient association, a media reports.

For subscribers

Pharma & biotech

Novo Nordisk enters multimillion-dollar partnership to slow insulin resistance

Together with US-based Dewpoint, Novo Nordisk hopes to find drug candidates that can curb diabetic complications.

For subscribers

Ambu leadership, including CFO Thomas Schmidt (left), CEO Britt Meelby Jensen, and CMO Bassel Rifai, announced plans to raise capital during the company's capital markets day on Tuesday | Foto: Ulrich Fischer Skov Quistgaard

Medtech

Ambu ruled out raising capital in August – now it's "due diligence"

One analyst says the Danish medtech company’s goal to lower its gearing would have happened naturally over time.

For subscribers

Hearing health

GN board member steps down due to family health issues

The board of directors at the hearing company will continue with one less member.

For subscribers

Medtech

FDA issues warning letter to Olympus

The Japanese medtech company once again finds itself in the crosshairs of the US drug regulator, while Danish competitor Ambu thinks the situation could push the market toward single-use products.

For subscribers

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Zealand Pharma presents positive early-stage results for weight-loss candidate

Did you read?

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Genmab promotes senior VP for strategy to executive management

Ambu wins European approval of two fifth-generation bronchoscopes

Sign up for our newsletter

Jobs

Novo Nordisk chair boasts competitive production advantage

Did you read?

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

Production at contaminated CMO continues – authorities deny further risks

Indian generic drugmaker to launch Leo Pharma copycat drug in US

EU delays new drug law proposal

Did you read?

Novo Nordisk enters collaboration with AI-driven drug discovery company

Article series: Pharma & biotech

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Novo Nordisk enters collaboration with AI-driven drug discovery company

California moves forward with making biosimilar insulin

Most read

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

Top news from MedWatch this week

Ambu share offering complete at 4.7% discount

Nordnet sees reason in Ambu's speedy capital raise

Novo Nordisk board discussed supply issues at every meeting in 2022

Novo Holdings could earn big on acquisition bid for Synlab

Patient group did not disclose Novo Nordisk ties in obesity treatment campaign

Novo Nordisk enters multimillion-dollar partnership to slow insulin resistance

Ambu ruled out raising capital in August – now it's "due diligence"

GN board member steps down due to family health issues

FDA issues warning letter to Olympus

Jobs